Philips launches global patient education effort for World COPD Day en andere bericht

Alleen voor leden beschikbaar, wordt daarom gratis lid!

Overig advies 12/11/2018 15:26
Campaign focuses on inspiring COPD patients to remain active for an improved quality of life

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of a global initiative to celebrate everyday wins by patients, providers and caretakers regarding the management of chronic obstructive pulmonary disease (COPD). Launching on World COPD Day on November 21, this awareness and celebratory campaign aims to help inspire COPD patients and their caregivers around ways to improve their overall quality of life.

COPD is a progressive, life-threatening disease that is estimated to effect more than 251 million people globally and is estimated to be the third leading cause of death by 2020 [1],[2]. In the U.S. alone, it is estimated that 12 million adults have COPD, with another 12 million going undiagnosed [3]. Despite the number of people impacted by this disease, there is limited awareness and a stigma associated with the disease, and once patients receive the diagnosis, they often don’t know how to overcome the shock of the disease.

“COPD often presents challenges for patients to partake in daily activities,” said Dr. Teofilo Lee-Chiong, chief medical liaison at Philips. “While COPD is a chronic condition, it doesn’t need to be a debilitating disease. With new advancements like connected care technology, patients have the opportunity to maintain their quality of life by receiving treatment at home through remote monitoring capabilities, as well as having access to their physicians for any questions around their illness or therapy pathway. These solutions also provide patients with a stronger support network, allowing the local care team to keep patients motivated and assist with their day-to-day activities. Through a positive outlook, an active lifestyle and adherence to therapy, patients with COPD can take back control of their lives.”

For COPD patients, Philips offers the following tips for living well and remaining active:•Have a positive mindset – Alter your outlook on the disease and understand the key to remaining active lies within the individual.
•Define your goals – Ask yourself what you would like to be able to do. Set short- and long-term goals for yourself.
•Exercise sensibly – Exercise can help strengthen large muscle groups and improve airway circulation. Work toward enhancing strength, endurance and flexibility by breaking down tasks into smaller parts and schedule frequent rest periods.
•Maintain a healthy lifestyle – Sustain a healthy diet with proper nutrition and adequate sleep. A poor diet can make symptoms worse and affect the ability to exercise.
•Be patient – Understand that progress takes time. With exercise and a healthy diet, your strength and endurance can recover.

This World COPD Day, each hour we will post real life “wins” patients around the world are experiencing each day to motivate them through the management of their COPD challenges. Philips offers a variety of COPD and respiratory disease management solutions that provide treatment from hospital to home, while empowering patients to live an active lifestyle. For more information on Philips COPD solutions or to help spread awareness for COPD patients globally, visit Philips.com/WorldCOPDDay. Follow the World COPD Day 2018 conversation on Twitter @PhilipsResp and at Facebook.com/PhilipsRespiratoryWellness.

[1] Global Burden of Disease Study, World Health Organization 2016
[2] Global Initiative for Chronic Obstructive Lung Disease. 2017. Retrieved from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd
[3] COPD Foundation; Retrieved from: https://www.copdfoundation.org/What-is-COPD/Understanding-COPD/Statistics.aspx

Philips announces first U.S. patient enrolled in ILLUMENATE study of Stellarex 0.014 Drug-Coated Balloon for below-the-knee peripheral artery disease.

tudy will assess safety and effectiveness of treatment that restores adequate blood flow in legs of patients to reduce repeat revascularizations and amputations of major lower limbs

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced enrollment of the first U.S. patient in the Stellarex ILLUMENATE Below-the-Knee (BTK) Investigational Device Exemption (IDE) study, led by principal investigators Dr. Bill Gray and Dr. Mahmood K. Razavi. This unique global, prospective, randomized, multi-center trial is designed to assess safety and effectiveness of the Stellarex 0.014 drug-coated balloon versus percutaneous transluminal angioplasty (PTA) in patients with critical limb ischemia (CLI). The trial will enroll 354 patients at 45 sites in U.S., Europe and Australia in the next 12-18 months. The first patient in the U.S. was enrolled by Dr. Craig Walker at the Cardiovascular Institute of the South in Houma, Louisiana.

"Several studies have shown the safety and durability benefits of the Stellarex balloon,” said Mahmood K. Razavi, MD, FSIR, FSVM, St. Joseph’s Hospital in Orange, CA and principal investigator of the ILLUMENATE BTK study. “This study will look at findings that continue to demonstrate the benefits of the Stellarex 0.014 Drug-Coated Balloon for BTK peripheral artery disease (PAD) and its safety and durability for patients. Given the challenging chronic nature of BTK PAD, we are hoping to find that through sustained patency using Stellarex, we can improve healing, and reduce target lesion revascularization and major amputation."

“Peripheral artery disease below the knee is challenging and Philips is committed to providing proven clinical solutions that positively impact patient outcomes,” said Christopher Barys, Image Guided Therapy Devices Business Leader for Philips. “With Stellarex BTK, we have the potential to improve patient outcomes and decrease re-admission costs for those suffering from this complex disease state, while providing clinicians with the necessary tools to confirm the right therapies for their patients.”

PAD is prevalent in the U.S. and affects around 250 million people worldwide [1]. If left untreated, the condition can lead to chronic limb ischemia (CLI). CLI associated with infrapopliteal arteries behind the knee often involves long calcified segments [2]. The prognosis is worse in elderly patients with severe comorbidities and limited life expectancy [3]. Therefore, the endovascular treatment of CLI remains a challenge for physicians. In the U.S., 160,000 – 180,000 amputations are performed annually, with more than 50 percent of cases having no diagnostic or therapeutic endovascular intervention performed in the year before an amputation [4].

Philips’ image-guided therapy solutions comprise interventional imaging systems, smart devices, software and services that enable clinicians to decide, guide, treat and confirm the appropriate cardiac and peripheral vascular treatment. By designing intelligent technologies and services that help clinicians to deliver a consistent standard of care, optimize care pathways and integrate workflows, Philips is enabling better patient and population outcomes.

The Stellarex 0.014” OTW Drug-Coated Balloon is designed to restore and maintain blood flow to arteries in patients with peripheral arterial disease. The Stellarex 0.014 Drug-Coated Balloon is CE Marked and available in Europe.

To find out more about Philips’ image-guided therapy solutions visit us at VEITHsymposium in the Philips pavilion (Nassau Suites), taking place in New York, November 13-16.

[1] Shu J, Santulli G. Update on peripheral artery disease: Epidemiology and evidence-based facts. Atherosclerosis. 2018;275:379-381.
[2] Mustapha JA, Diaz-Sandoval LJ, Saab F. Infrapopliteal calcification patterns in critical limb ischemia: diagnostic, pathologic and therapeutic implications in the search for the endovascular holy grail. J Cardiovasc Surg 2017;58:383-401. DOI: 10.23736/S0021-9509.17.09878-0.
[3] Cardiovasc Intervent Radiol. 2018 Jan;41(1):1-20. doi: 10.1007/s00270-017-1796-9. Epub 2017 Sep 18. Predictive Parameters for Clinical Outcome in Patients with Critical Limb Ischemia Who Underwent Percutaneous Transluminal Angioplasty (PTA): A Systematic Review. Schreuder SM1, Hendrix YMGA2, Reekers JA2, Bipat S2.
[4] Sanguily III, J., Martinsen, B. J., Igyarto, Z., Pham,M.T. Reducing Amputation Rates in Critical Limb Ischemia Patients Via a Limb Salvage Program: A Retrospective Analysis. Vascular Disease Management. 2016;13(5):E112-E119.



Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord


Copyrights © 2000 by XEA.nl all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.


Copyrights © DEBELEGGERSADVISEUR.NL